Heart biopsy study aims to unlock secrets of heart failure
NCT ID NCT06517186
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at heart tissue from 180 people with a type of heart failure called HFpEF. Researchers take tiny samples of heart muscle during a routine procedure to find changes in the tissue. The goal is to learn what causes this condition so better treatments can be developed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults over 30 years of age.
- Ages
-
30 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * HFpEF criteria 1. Age ≥30 years. 2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability) 3. Definition of HFpEF: signs and/or symptoms of HF, NYHA functional class II-IV, and at least one of the following: 1. Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center. 2. Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels \[using the thresholds listed above\], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography). 3. Previously documented elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise). 4. Elevated H2FPEF score69 (≥5) or HFA-PEFF70 score (≥5). Suspected HFpEF criteria 1. Age ≥30 years. 2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability) 3. Signs and/or symptoms of HF, NYHA functional class II-IV and all of the following: 1. Does not meet BNP or NT-proBNP criteria for HFpEF (above) 2. No prior HF hospitalization meeting HF criteria (above) 3. No previous hemodynamic catheterization documentation of HF (as above) Exclusion Criteria: * 1\. Inadequate echo or fluoroscopic images. 2\. Neck anatomy unfavorable for jugular venous cannulation 3\. Therapy with direct oral anticoagulants without cessation for a period (age, renal function, and agent specific) deemed adequate to normalize coagulation according to local clinical guidelines. 4\. Previous or ongoing therapy with warfarin with INR ≥ 1.6 measured day before or of EMB 5\. Platelet count \< 50,000/ml 6\. Active bleeding or coagulation disorder 7\. Infection or fever 8\. Endocarditis 9\. Pregnancy 10\. Intracardiac thrombus 11\. RV Aneurysm 12\. Clinically significant tricuspid, pulmonary or aortic valve stenosis 13\. Tricuspid or pulmonary mechanical valve prosthesis 14\. Left bundle branch block
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
-
Mass General Brigham
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Wake Forest University
RECRUITINGWinston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can biomarkers predict which elderly heart failure patients will return to hospital?
- Can a daily pill shield hearts in HFpEF?
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?